Next report date
Report period
Q1 2024
EPS estimate
−0.76USD
Revenue estimate
—
−2.87USD
−75.52 MUSD
17.48 M
About Aerovate Therapeutics, Inc.
Sector
Industry
CEO
Timothy P. Noyes
Website
Headquarters
Waltham
Employees (FY)
51
Founded
2018
FIGI
BBG00WGHZFH4
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AVTE is 21.57 USD — it has increased by 1.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aerovate Therapeutics, Inc. stocks are traded under the ticker AVTE.
Aerovate Therapeutics, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
AVTE stock is 11.60% volatile and has beta coefficient of 2.64. Check out the list of the most volatile stocks — is Aerovate Therapeutics, Inc. there?
AVTE earnings for the last quarter are −0.71 USD per share, whereas the estimation was −0.69 USD resulting in a −2.50% surprise. The estimated earnings for the next quarter are −0.68 USD per share. See more details about Aerovate Therapeutics, Inc. earnings.
Yes, you can track Aerovate Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
AVTE stock has fallen by 3.88% compared to the previous week, the month change is a 18.76% fall, over the last year Aerovate Therapeutics, Inc. has showed a 15.10% increase.
AVTE net income for the last quarter is −20.41 M USD, while the quarter before that showed −19.56 M USD of net income which accounts for −4.34% change. Track more Aerovate Therapeutics, Inc. financial stats to get the full picture.
Today Aerovate Therapeutics, Inc. has the market capitalization of 590.70 M, it has decreased by 6.14% over the last week.
No, AVTE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AVTE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aerovate Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 51.00 employees. See our rating of the largest employees — is Aerovate Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aerovate Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aerovate Therapeutics, Inc. stock shows the buy signal. See more of Aerovate Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Aerovate Therapeutics, Inc. future price: according to them, AVTE price has a max estimate of 65.00 USD and a min estimate of 27.00 USD. Read a more detailed Aerovate Therapeutics, Inc. forecast: see what analysts think of Aerovate Therapeutics, Inc. and suggest that you do with its stocks.